Journal for ImmunoTherapy of Cancer (Nov 2020)
684 A low affinity bivalent mesothelin-binding MATCH4 multispecific T cell engager increases cytotoxic selectivity for high mesothelin expressing cells
- Bithi Chatterjee,
- Alexandre Simonin,
- Daniel Snell,
- Tea Gunde,
- Christian Hess,
- Matthias Brock,
- Stefan Warmuth,
- Christopher Weinert,
- Niels Kirk,
- Dania Diem,
- Naomi Flückiger,
- Robin Heiz,
- Benjamin Küttner,
- Dana Mahler,
- Diego Morenzoni,
- Sandro Wagen,
- Julia Zeberer,
- David Urech
Affiliations
- Bithi Chatterjee
- Numab Therapeutics, Wadenswil, Switzerland
- Alexandre Simonin
- Numab Therapeutics, Wadenswil, Switzerland
- Daniel Snell
- Numab Therapeutics, Wadenswil, Switzerland
- Tea Gunde
- Numab Therapeutics, Wadenswil, Switzerland
- Christian Hess
- Numab Therapeutics, Wadenswil, Switzerland
- Matthias Brock
- Numab Therapeutics, Wadenswil, Switzerland
- Stefan Warmuth
- Numab Therapeutics, Wadenswil, Switzerland
- Christopher Weinert
- Numab Therapeutics, Wadenswil, Switzerland
- Niels Kirk
- Numab Therapeutics, Wadenswil, Switzerland
- Dania Diem
- Numab Therapeutics, Wadenswil, Switzerland
- Naomi Flückiger
- Numab Therapeutics, Wadenswil, Switzerland
- Robin Heiz
- Numab Therapeutics, Wadenswil, Switzerland
- Benjamin Küttner
- Numab Therapeutics, Wadenswil, Switzerland
- Dana Mahler
- Numab Therapeutics, Wadenswil, Switzerland
- Diego Morenzoni
- Numab Therapeutics, Wadenswil, Switzerland
- Sandro Wagen
- Numab Therapeutics, Wadenswil, Switzerland
- Julia Zeberer
- Numab Therapeutics, Wadenswil, Switzerland
- David Urech
- Numab Therapeutics, Wadenswil, Switzerland
- DOI
- https://doi.org/10.1136/jitc-2020-SITC2020.0684
- Journal volume & issue
-
Vol. 8,
no. Suppl 3
Abstract
No abstracts available.
